There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Recent studies of inhaled corticosteroid (ICS) therapy for managing stable chronic
obstructive pulmonary disease (COPD) have yielded conflicting results regarding survival
and risk of adverse events.